Showing 1716 results
-
Press release /Positive opinion is based on comprehensive data confirming that Sandoz biosimilar pegfilgrastim matches the reference medicine in terms of safety, efficacy and qualitySandoz seeks approval in the…
-
Press release /Global ELARA trial demonstrated clinically meaningful benefit in patients with relapsed or refractory (r/r) follicular lymphoma (FL) as measured by complete response rate Kymriah previously…
-
Press release /Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in annual cumulative steroid dose vs placebo…
-
Story /A conversation with Novartis Chief Digital Officer Bertrand Bodson
-
Media Library / -
Press release /Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
-
Press release /Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of…
-
Press release /Ziextenzo™ is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy With approval of Ziextenzo™ , Sandoz is first and only…
-
Press release /Clareon® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy…